Fluorometholone

Fluorometholone Reactions 1680, p142 - 2 Dec 2017 Cushing’s syndrome: case report A 4 years-old boy developed Cushing’s syndrome (CS) during treatment with fluorometholone eye drops. The boy presented with the complaint of rapid weight gain. He had a BMI of 18.1 with a height of 99.9cm and a weight of 18.1kg. On presentation, his examination demonstrated moon facies. He had a diagnosis of allergic conjunctivitis and he had been receiving fluorometholone containing eye drops (0.1% solution) and netilmicin for one month. He was using 3 5 drops of fluorometholone a day. At basal hormonal evaluation, his cortisol level was 0.38 µg/dL and ACTH level was <5 pg/mL. An ACTH stimulation test was performed and peak cortisol level of 11.5 µg/dL was obtained at 60 minutes. These findings were consistent with adrenal insufficiency. Thereafter, the boy was recommended for hydrocortisone therapy, but his family was reluctant to hydrocortisone th treatment. Basal hormonal evaluation at the 4 month, showed the normal functioning of pituitary-adrenal axis. Additionally, his facial appearance became normal. Author comment: "In our patient, CS developed following the use of fluorometholone, a relatively less potent steroid compared to these other steroids." "Although eyedrops containing potent glucocorticoids may lead to CS, fluorometholone, a relatively less potent steroid, may also cause the syndrome, as in our case." Ustyol A, et al. Cushing’s syndrome caused by use of synthetic ocular steroid. Journal of Clinical Pharmacy and Therapeutics 42: 780-782, No. 6, Dec 2017. Available from: URL: http://doi.org/10.1111/jcpt.12573 - Turkey 803284590 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Fluorometholone

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/fluorometholone-OkScOb5a2L
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39073-4
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial